Santero Therapeutics
Santero Therapeutics is dedicated to developing innovative antibiotics to combat antimicrobial resistance, a major global health challenge. The company focuses on discovering first-in-class small molecules targeting multidrug-resistant pathogens, with a mission to improve public health through new therapeutic solutions. It is a spin-off of the Université Libre de Bruxelles, founded in 2021, with a research background spanning nearly 20 years. Santero aims to create a technological platform for developing a new generation of antibiotics effective against both Gram-positive and Gram-negative bacteria, including resistant strains. The company is advancing through lead optimization phases and is actively involved in scientific research, fundraising, and collaborations with public partners.
Industries
Nr. of Employees
small (1-50)
Santero Therapeutics
Products
First-in-class small-molecule RSH enzyme inhibitor candidate
A preclinical small-molecule candidate that inhibits the bacterial RSH stress-response enzyme, showing bactericidal activity against Staphylococcus aureus and in vitro activity against resistant strains; demonstrated in vivo efficacy for lead series.
First-in-class small-molecule RSH enzyme inhibitor candidate
A preclinical small-molecule candidate that inhibits the bacterial RSH stress-response enzyme, showing bactericidal activity against Staphylococcus aureus and in vitro activity against resistant strains; demonstrated in vivo efficacy for lead series.
Services
End-to-end preclinical activities including target validation, hit-to-lead discovery, lead optimization, in vivo efficacy studies, and preparation for IND-enabling work.
End-to-end preclinical activities including target validation, hit-to-lead discovery, lead optimization, in vivo efficacy studies, and preparation for IND-enabling work.
Expertise Areas
- Antimicrobial resistance research
- Small-molecule antibiotic discovery
- Target identification and validation
- Lead optimization
Key Technologies
- Enzyme-targeted small-molecule inhibitors
- Alarmone-pathway (stress-response) inhibition
- Machine learning–driven compound screening
- Hit-to-lead medicinal chemistry
News & Updates
Gokhan Batur, an experienced biotech leader, was appointed as Chairman in April 2025, bringing strategic guidance to the company's development.
Santero showcased its latest research and in vivo efficacy results at the AMR Conference in Basel, emphasizing its commitment to combating antimicrobial resistance.
Recent research by Santero could contribute to solving a serious public health problem related to bacterial infections.
An article highlighting Santero's efforts and innovations in addressing antibiotic resistance, supported by public and private investments.
L'Echo reports on Santero's novel approach to antibiotic development, emphasizing its potential to impact public health.
Gokhan Batur, an experienced biotech leader, was appointed as Chairman in April 2025, bringing strategic guidance to the company's development.
Santero showcased its latest research and in vivo efficacy results at the AMR Conference in Basel, emphasizing its commitment to combating antimicrobial resistance.
Recent research by Santero could contribute to solving a serious public health problem related to bacterial infections.
An article highlighting Santero's efforts and innovations in addressing antibiotic resistance, supported by public and private investments.
L'Echo reports on Santero's novel approach to antibiotic development, emphasizing its potential to impact public health.